| Dec'19 | Mar'19 | Dec'18 | Mar'18 | Mar'17 | ||
|---|---|---|---|---|---|---|
Revenues: | ||||||
Total revenues | ||||||
3,364 | - | 2,442 | - | - | ||
Cost of revenues | ||||||
3,304 | - | 2,627 | - | - | ||
Gross profit/(loss) | ||||||
60 | - | -185 | - | - | ||
Operating expenses: | ||||||
Sales and marketing | ||||||
6,303 | - | 2,806 | - | - | ||
Research and development | ||||||
2,497 | - | 2,054 | - | - | ||
General and administrative | ||||||
8,865 | - | 3,515 | - | - | ||
Total operating expenses | ||||||
17,665 | 1,978 | 8,375 | 306 | 0 | ||
Loss from operations | ||||||
-17,605 | -1,978 | -8,560 | -306 | -0 | ||
Other expense: | ||||||
Gain on debt extinguishment | ||||||
928 | - | - | - | - | ||
Interest expense, net | ||||||
-2,657 | - | -1,093 | - | - | ||
Other expense | ||||||
-355 | - | -351 | - | - | ||
Total other expense | ||||||
-2,084 | - | -1,444 | - | - | ||
Interest income | ||||||
- | 2,863 | - | 1,208 | - | ||
Interest income | ||||||
- | - | - | - | 0 | ||
Unrealized gain (loss) on marketable securities held in Trust Account | ||||||
- | 59 | - | -45 | 0 | ||
Net loss and comprehensive loss | ||||||
-19,689 | 944 | -10,004 | 856 | -0 | ||
Weighted average shares outstanding used in computing net loss per share, basic and diluted | ||||||
7,005 | 5,136 | 4,410 | 4,721 | 3,750 | ||
Net loss per common share outstanding, basic and diluted | ||||||
-2.81 | 0.14 | -2.27 | -0.05 | 0.00 | ||
Assay Revenue | ||||||
Total revenues | ||||||
1,403 | - | 1,281 | - | - | ||
Contract Revenue | ||||||
Total revenues | ||||||
1,961 | - | 1,161 | - | - | ||